Online first
Clinical vignette
Published online: 2024-11-25
Clinical outcomes and long-term follow-up after radioligand therapy in aggressive non-functioning pituitary neuroendocrine tumour
1
, 1, 1, 1, 1, 1
, 1, 1, 1, 1, 1
Abstract
Not required for Clinical Vignette.
Keywords: pituitary neuroendocrine tumour (PitNET)aggressive pituitary tumournon-functioning pituitary tumour (NF-PitNET)radionuclide ligand therapy (RLT)somatostatin receptors (SSTR)177Lu-DOTATATE
References
- Raverot G, Burman P, McCormack A, et al. European Society of Endocrinology. European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas. Eur J Endocrinol. 2018; 178(1): G1–G24.
- Nakano-Tateno T, Lau KJ, Wang J, et al. Multimodal Non-Surgical Treatments of Aggressive Pituitary Tumors. Front Endocrinol (Lausanne). 2021; 12: 624686.
- Harris PE, Zhernosekov K. The evolution of PRRT for the treatment of neuroendocrine tumors; What comes next? Front Endocrinol (Lausanne). 2022; 13: 941832.
- Marques P. The Effects of Peptide Receptor Radionuclide Therapy on the Neoplastic and Normal Pituitary. Cancers (Basel). 2023; 15(10).
- Ilie MD, Raverot G. Treatment Options for Gonadotroph Tumors: Current State and Perspectives. J Clin Endocrinol Metab. 2020; 105(10).
